Telix Pharmaceuticals Enters Commercial Distribution Agreement for Prostate Cancer Diagnostic
Indianapolis IN and Columbus OH (U.S.A) – 8 April 2020. Telix Pharmaceuticals (U.S.) Inc. is pleased to announce it has entered into a commercial agreement with Cardinal Health
Telix Pharmaceuticals (U.S.) Inc. (‘Telix U.S.A’), a subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce it has entered into a definitive commercial agreement with Columbus-based Cardinal Health to provide radiopharmacy and logistics services to support Telix’s prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of metastatic prostate cancer.
Under the agreement, Cardinal Health will prepare and deliver patient-specific unit-doses of Telix’s prostate cancer imaging product TLX591-CDx, for the U.S.
To read the full media release click here.